Drug Development Technology is using cookies

We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.

ContinueLearn More X
X

Alunbrig (brigatinib) for the Treatment of Non-Small Cell Lung Cancer (NSCLC)

Drug (Brand / Generic)

Alunbrig / brigatinib

Developer

Takeda Pharmaceutical Company

Therapy Class

Tyrosine kinase inhibitor

Current Indication

Non-small cell lung cancer

Market Sector

Oncology

Development Status

Approved in the US
Expand

Go Top